JP2008506357A5 - - Google Patents

Download PDF

Info

Publication number
JP2008506357A5
JP2008506357A5 JP2007505491A JP2007505491A JP2008506357A5 JP 2008506357 A5 JP2008506357 A5 JP 2008506357A5 JP 2007505491 A JP2007505491 A JP 2007505491A JP 2007505491 A JP2007505491 A JP 2007505491A JP 2008506357 A5 JP2008506357 A5 JP 2008506357A5
Authority
JP
Japan
Prior art keywords
env
seq
protein
env protein
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007505491A
Other languages
English (en)
Japanese (ja)
Other versions
JP5060284B2 (ja
JP2008506357A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/003339 external-priority patent/WO2005095442A1/en
Publication of JP2008506357A publication Critical patent/JP2008506357A/ja
Publication of JP2008506357A5 publication Critical patent/JP2008506357A5/ja
Application granted granted Critical
Publication of JP5060284B2 publication Critical patent/JP5060284B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007505491A 2004-03-30 2005-03-30 ウイルスタンパク質の免疫抑制作用のモデュレーションに関与するポリペプチド配列 Expired - Fee Related JP5060284B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04290838 2004-03-30
EP04290838.4 2004-03-30
PCT/EP2005/003339 WO2005095442A1 (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Publications (3)

Publication Number Publication Date
JP2008506357A JP2008506357A (ja) 2008-03-06
JP2008506357A5 true JP2008506357A5 (enExample) 2011-02-03
JP5060284B2 JP5060284B2 (ja) 2012-10-31

Family

ID=34896141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007505491A Expired - Fee Related JP5060284B2 (ja) 2004-03-30 2005-03-30 ウイルスタンパク質の免疫抑制作用のモデュレーションに関与するポリペプチド配列

Country Status (14)

Country Link
US (2) US8178657B2 (enExample)
EP (1) EP1732585B1 (enExample)
JP (1) JP5060284B2 (enExample)
CN (1) CN1961001B (enExample)
AT (1) ATE472334T1 (enExample)
AU (1) AU2005229411B2 (enExample)
BR (1) BRPI0509497B1 (enExample)
CA (1) CA2561376C (enExample)
DE (1) DE602005022056D1 (enExample)
ES (1) ES2347445T3 (enExample)
IL (1) IL178205A (enExample)
MX (1) MXPA06011272A (enExample)
WO (1) WO2005095442A1 (enExample)
ZA (1) ZA200608178B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
EP2402447A1 (en) 2005-03-30 2012-01-04 Viroxis Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US20080299150A1 (en) * 2007-05-08 2008-12-04 Sankhia Corporation Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
RU2008140688A (ru) * 2008-10-15 2010-04-20 Михаил Аркадьевич Шурдов (RU) Иммуносупрессивный пептид
WO2010079208A1 (en) 2009-01-09 2010-07-15 Centre National De La Recherche Scientifique New receptor binding ligands, their use in the detection of cells with biological interest
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
WO2012035369A1 (en) * 2010-09-17 2012-03-22 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
RS58289B1 (sr) * 2011-07-20 2019-03-29 Merial Ltd Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije
US9636396B2 (en) 2011-12-07 2017-05-02 Centre National De La Recherche Scientifique Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
EP2788372B1 (en) * 2011-12-07 2019-07-10 Viroxis S.A.S. Mutated lentiviral env proteins and their use as drugs
CA2912354C (en) 2013-06-07 2023-01-24 Viroxis S.A.S. Mutated non-primate lentiviral env proteins and their use as drugs
JP6864364B2 (ja) * 2015-06-11 2021-04-28 学校法人慶應義塾 融合タンパク質又は複合タンパク質、細胞内送達用担体、部分ペプチド、細胞膜透過促進剤、dna、及びベクター
CA2999792A1 (en) * 2015-10-01 2017-04-06 Magdalena Janina LASKA Use of human derived immunosuppressive proteins and peptides as medicaments
US11351247B2 (en) 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease
US20210403907A1 (en) 2018-09-18 2021-12-30 Vnv Newco Inc. Arc-based capsids and uses thereof
EP3852813A4 (en) 2018-09-18 2022-06-22 VNV Newco Inc. ARC-BASED CAPSIDS AND THEIR USES
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
US20240093233A1 (en) 2021-01-13 2024-03-21 Viroxis Measles-hiv or measles-htlv vaccine
EP4392053A4 (en) * 2021-08-23 2025-06-25 Gabet, Yankel COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE DISEASES OR CONDITIONS
WO2024218400A1 (en) 2023-04-21 2024-10-24 Inprother Aps Improved expression of surface-displayed antigens
CN121717880A (zh) * 2025-12-25 2026-03-24 中国海洋大学青岛海上丝路研究院 许氏平鲉内源性逆转录病毒包膜蛋白percomORF、慢病毒载体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
EP0377842B1 (en) 1988-12-13 1995-10-04 President And Fellows Of Harvard College Prototype FeLV isolates for use in disease models and vaccines
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
WO2001031021A1 (en) * 1999-10-28 2001-05-03 Universite De Geneve Multiple sclerosis-related superantigen
CA2429755A1 (en) * 2000-12-11 2002-06-20 Tufts University Treatment and prevention of ebv infection and ebv-associated disorders
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition

Similar Documents

Publication Publication Date Title
US20250327065A1 (en) Disulfide-rich peptide libraries and methods of use thereof
Chappell et al. Expression levels of MHC class I molecules are inversely correlated with promiscuity of peptide binding
Dietrich et al. Peptides as drugs: from screening to application
JP7274228B2 (ja) 病気の治療のためのポリペプチド
JP2009525757A5 (enExample)
JP6047231B2 (ja) β−ヘアピンペプチド模倣薬
JP2018171063A5 (enExample)
CN115246874B (zh) 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用
JP2011523550A5 (enExample)
JP2023504914A5 (enExample)
KR20180030506A (ko) 상피 난소암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
KR20180012865A (ko) 골수종 및 기타 암의 면역요법에서의 사용을 위한 신규 세포 에피톱 및 세포 에피톱의 조합
JP2019506839A5 (enExample)
RU2007126553A (ru) Упорядоченные ряды антигенов ил-15 и их применение
Iglesias et al. Structural information in therapeutic peptides: emerging applications in biomedicine
Hirsch et al. Identification of a new subgroup of SIVagm in tantalus monkeys
USRE44747E1 (en) Mapping and reconstitution of a conformational discontinuous binding surface
JP2022506715A (ja) ストレス症候群、免疫反応症候群及び卒中症候群の処置のためのポリペプチド
CN100577686C (zh) 寡聚肽及其治疗hiv感染的用途
CN112543765A (zh) 能够刺激细胞因子释放的新型肽及其衍生物
JP2009062372A (ja) 高分子質量レクチンの生産
Olmez et al. Protein-peptide interactions revolutionize drug development
JP2024539609A5 (enExample)
JP2023541764A5 (enExample)
JP2019525764A5 (enExample)